Table 1 |
||||
|
Cytokine/chemokine biomarkers identified in the literature search (with some selected references) |
||||
|
Sepsis marker |
Evaluated in experimental studies |
Evaluated in clinical studies |
Evaluated as a prognostic factor |
Comment |
|
|
||||
|
√ |
C (m) |
√ |
Higher in septic shock than in sepsis |
|
|
√ |
C |
√ |
No difference between survivors and non-survivors at 28 days |
|
|
√ |
A |
√ |
Correlation with SOFA score |
|
|
√ |
A |
Increased in septic compared with non-septic individuals |
||
|
IL-2 [58] |
B |
√ |
Increased in parallel with disease severity |
|
|
IL-4 [59] |
C (s) |
√ |
Increased levels associated with development of sepsis |
|
|
√ |
B |
√* |
Distinguished between survivors and non-survivors at 28 days |
|
|
B |
√*** |
Prediction of MOF, DIC |
||
|
√ |
B |
√** |
Higher in septic shock than sepsis, distinguished between survivors and non-survivors at 28 days |
|
|
√ |
C |
√ |
Predictive of lethal outcome from postoperative sepsis |
|
|
√ |
B |
√ |
Higher in septic shock than sepsis |
|
|
√ |
B(s) |
√ |
Distinguished between survivors and non-survivors at 28 days |
|
|
√ |
A |
√ |
Increased in sepsis compared with healthy controls |
|
|
√ |
A |
√** |
Distinguished between survivors and non-survivors at 28 days |
|
|
√ |
B |
√* |
Distinguished between survivors and non-survivors at 28 days |
|
|
Osteopontin [75] |
B |
Increased in sepsis compared with healthy controls |
||
|
√ |
B |
Increased in sepsis compared with healthy controls |
||
|
√ |
C |
√ |
Distinguished between survivors and non-survivors at 28 days in patients with septic shock |
|
|
|
||||
|
*sensitivity and specificity of less than 90%; **sensitivity of more than 90% but specificity of less than 90%; ***sensitivity and specificity more than 90%; A, Clinical study with less than 20 patients; B, Clinical study with 20 to 50 patients; C, Clinical study with more than 50 patients; (s), surgical patients only; (m), medical patients only. DIC: disseminated intravascular coagulopathy; MOF: multiple organ failure; SOFA: sequential organ failure assessment. |
||||
|
Pierrakos and Vincent Critical Care 2010 14:R15 doi:10.1186/cc8872 |
||||